90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00100230 (ClinicalTrials.gov) | September 2004 | 27/12/2004 | DHA and X-Linked Retinitis Pigmentosa | Investigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis Pigmentosa | Retinitis Pigmentosa;X-linked Genetic Diseases | Drug: docosahexaenoic acid OR corn/soy oil placebo | Retina Foundation of the Southwest | Foundation Fighting Blindness;DSM Nutritional Products, Inc. | Completed | 7 Years | 32 Years | Male | 78 | Phase 2 | United States |
| 2 | NCT00004827 (ClinicalTrials.gov) | March 1996 | 24/2/2000 | Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: docosahexaenoic acid | Retina Foundation of the Southwest | NULL | Completed | N/A | N/A | Male | 46 | N/A | NULL |